News

One study takes a look at how out-of-pocket costs impede the use of pre-exposure prophylaxis in young men who have sex with men.

Dr. Meg Watson from the CDC reports updated information regarding the current rates and trends of HIV diagnoses in the South at 2018 CROI.

At CROI 2018, Dr. Helen Weiss highlighted where we are in terms of meeting these goals, where the challenges are, and strategies to help prevent new infections.

Flu activity is down for the second week in a row in the United States, but as the flu season still has several weeks to go, the FDA has issued a warning about counterfeit flu medications.

New research from Australia supports the use of booster doses of the pneumococcal conjugate vaccine, but it shows overall effectiveness is high.

In an oral abstract session at CROI 2018, Dr. Nathan Thielman stresses that understanding the interest of HIV-positive treatment-experienced individuals in new antiretroviral therapies may help inform their development and uptake.

These landmark results are from a field study assessing the safety and efficacy of combination therapy with delamanid and bedaquiline in the treatment of drug-resistant tuberculosis.

Better understanding of the vaginal microbiome may provide new insights into HIV acquisition.

At CROI 2018, the World Health Organization released updated guidelines for cryptococcal disease in HIV-infected adults.

Study results revealed that dolutegravir appears to be effective and well-tolerated in HIV/tuberculosis (TB) co-infected adults also receiving rifampin-based TB therapy.

First detailed analysis by race and risk group finds that two-thirds of those who could benefit from PrEP are African American or Latino, but they account for the smallest percentage of prescriptions to date.

Week 48 safety results show that switching to B/F/TAF was noninferior to remaining on DTG/ABC/3TC.

Better understanding of the pathogenesis of tuberculosis can help inform the development of a new, effective vaccine.

The World Health Organization reports that declining vaccination rates caused a 4-fold increase in measles cases in Europe last year, which prompted European health ministers to convene a meeting to discuss efforts to eliminate the virus.

Week 24 safety and efficacy data on women who switched from a baseline regimen (SBR) to B/F/TAF were presented at CROI 2018.

More research is needed but characterizing the biologic risk factors associated with HIV that are specific to transgender women may be key to informing more effective preventive strategies.

Research suggests misperceptions about the risk of HIV infection should be corrected at the time of testing, with PrEP initiated same-day if appropriate.

Although antiretroviral therapy has led to significantly longer life expectancies among individuals with HIV, this, in turn, has contributed to the likelihood that these individuals will develop age-related comorbidities at earlier ages.

International interdisciplinary collaboration will bring us that much closer to a cure for HIV.

In case you missed them, we’ve compiled a list of the latest recalls posted this week.

The US Food and Drug Administration (FDA) has weighed in on the strains to be included in the 2018-2019 influenza vaccine.

In case you missed them, we’ve compiled the top five infectious disease articles from this past week.

An outbreak of Lassa fever in Nigeria that began at the start of the year has now soared to become the country’s biggest outbreak of the virus to date. Nigerian and global health officials are now working together to stop the outbreak.

The first global estimate of tuberculosis (TB) rates among young people find that about 1.8 million individuals in this age group develop the disease each year.

The new test can differentiate between Lyme disease and 7 other tick-borne diseases.

These deadly infections are often treated with combination therapy, but a new study finds no significant difference in outcomes when using a 2-drug regimen versus a single-drug regimen.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

CARB-X, the international partnership between governmental and charitable groups in the United States and the United Kingdom, has announced new funding for the development of new antibiotics to fight drug-resistant bacteria.